Therapeutic potential for KCC2-targeted neurological diseases

• Main Authors: Kazuo Tomita (Author), Yoshikazu Kuwahara (Author), Kento Igarashi (Author), Junichi Kitanaka (Author), Nobue Kitanaka (Author), Yuko Takashi (Author), Koh-ichi Tanaka (Author), Mehryar Habibi Roudkenar (Author), Amaneh Mohammadi Roushandeh (Author), Akihiro Kurimasa (Author), Yoshihiro Nishitani (Author), Tomoaki Sato (Author)
• Format: Book
• Published: Elsevier, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Patients with neurological diseases, such as schizophrenia, tend to show low K+-Cl- co-transporter 2 (KCC2) levels in the brain. The cause of these diseases has been associated with stress and neuroinflammation. However, since the pathogenesis of these diseases is not yet fully investigated, drug th...